Suven Life Sciences to Present Masupirdine and Tenaclidine Clinical Study Findings at CTAD 2026

manufacturing-news
Image Courtesy: Pixabay

Suven Life Sciences Limited, a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system (CNS) disorders, will present two scientific papers highlighting the clinical progress of its investigational drug candidates, Masupirdine (SUVN-502) and Tenaclidine (SUVN-I6107), at the 19th Clinical Trials on Alzheimer’s Disease (CTAD 2026) Conference in Boston, USA, being held from November 16 to 19, 2026.

The presentations will cover findings from the global Phase-3 clinical study of Masupirdine, being developed for the treatment of agitation in patients with dementia of the Alzheimer’s type, and the Phase-1 clinical evaluation of Tenaclidine, a potential treatment targeting cognitive disorders.

Masupirdine will be featured under presentation P033, titled “Masupirdine (SUVN-502), A Pure 5-HT6 Receptor Antagonist: Baseline Demographic and Clinical Characteristics of the Phase-3 Clinical Study Targeting Agitation in Patients with Dementia of Alzheimer’s Type”. The presentation will provide an overview of the baseline demographic and clinical characteristics of patients enrolled in the global Phase-3 study, which has completed patient enrolment.

The second presentation, P066, titled “Tenaclidine (SUVN-I6107), A Pure M1 Positive Allosteric Modulator: First-in-Human Evaluation of Safety, Tolerability and Pharmacokinetics in Healthy Subjects”, will outline findings from the Phase-1 single ascending dose (SAD) and multiple ascending dose (MAD) studies. The results will include assessments of safety, tolerability and pharmacokinetics, along with the effects of food, age and gender on the drug’s pharmacokinetic profile.

Commenting on the clinical development milestones, Venkat Jasti, Chairman and Managing Director of Suven Life Sciences, said the completion of enrolment in the global Phase-3 Masupirdine agitation study marked an important achievement. He noted that the baseline characteristics were consistent with published studies and represented an appropriate Alzheimer’s disease population with agitation. No major safety concerns had been identified to date, and the company expects to announce topline results in the second quarter of 2027.

He further expressed encouragement over the clinical findings for Tenaclidine, which support the company’s plans to advance the candidate towards patient studies. The progress of both programmes reflects Suven’s continued focus on developing innovative treatment approaches for CNS disorders with significant unmet medical needs.

CTAD is an international scientific conference dedicated to Alzheimer’s disease research. It brings together clinical investigators, healthcare professionals, pharmaceutical industry scientists and regulatory experts to discuss developments in disease prevention, diagnosis and treatment. The conference provides a platform for sharing clinical research findings and facilitating collaboration among stakeholders working to advance Alzheimer’s disease care.

Suven Life Sciences Limited is engaged in the discovery and clinical development of innovative medicines addressing unmet medical needs in central nervous system disorders. Its research and development programmes cover Alzheimer’s disease, sleep disorders, major depressive disorder, Parkinson’s disease, schizophrenia, pain and gastrointestinal disorders.

The company’s clinical pipeline comprises five key assets. Masupirdine (SUVN-502), being developed for agitation in patients with dementia of the Alzheimer’s type, is in global Phase-3 development, with enrolment completed. Samelisant (SUVN-G3031), targeting excessive daytime sleepiness in narcolepsy, has completed its Phase-2 study, while its pivotal Phase-3 AWAKE study has commenced. A Phase-2 study for cataplexy is also in planning.

Ropanicant (SUVN-911), being developed for major depressive disorder, has completed its open-label Phase-2a and double-blind, randomised, placebo-controlled Phase-2b studies, with Phase-3 development in planning. Usmarapride (SUVN-D4010), targeting cognitive disorders, is preparing for Phase-2 development. Tenaclidine (SUVN-I6107), another candidate for cognitive disorders, has completed its Phase-1 clinical study, while long-term general and developmental toxicity studies in non-clinical models are underway. In addition to these clinical-stage programmes, Suven has seven projects in its research pipeline across multiple indications. The company owns the intellectual property rights to its drug development assets in all major markets worldwide.